A dry Home Office statutory instrument it may be, but this one says something important about how the UK still works after Brexit. The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026, Statutory Instrument 2026 No. 607, were made on 8 June 2026 and come into force on 29 June, setting out one legal route for Great Britain and another for Northern Ireland when it comes to the control and trade of drug precursor chemicals. On paper, the change is about definitions, authorisations and revoked instruments. In practice, it is another clear example of the Windsor Framework shaping everyday regulation well beyond the usual rows about food, parcels or customs. This time, the split shows up in the rules around chemicals that can be used to make illegal drugs.

The legislation.gov.uk text makes plain that the regulations amend the 2008 and 2010 controlled drugs rules rather than starting again from scratch. The key move is to separate the meaning of the relevant Community Regulation depending on where the law is being applied: in Northern Ireland, the EU versions continue as they have effect in EU law; in Great Britain, the equivalent rules sit as domestic assimilated law. That distinction matters. It means ministers are not pretending there is one neat UK-wide regime here. They are writing the divide directly into the statute book, with Northern Ireland still tied to the EU framework in this area and Great Britain working from its own adapted text.

The reason sits in Article 5(4) of the Windsor Framework. As the explanatory note says, EU law listed in Annex 2 continues to apply in and to the UK in respect of Northern Ireland, and both Regulation (EC) No. 273/2004 and Council Regulation (EC) No. 111/2005 are on that list. That is why so much of this instrument is taken up with replacing references to 'the United Kingdom' with 'Great Britain'. It sounds technical, but the wording carries real weight. In this field, the law is acknowledging that Northern Ireland is not being treated the same as England, Scotland and Wales, because the post-Brexit settlement says it cannot be.

For operators moving scheduled substances, the practical side sits in the authorisations and customs rules. The explanatory note says the procedures under Regulation (EC) No. 111/2005 will apply to the movement of drug precursor chemicals between Great Britain and Northern Ireland, and the Northern Ireland provisions set out how import and export authorisations are to be handled when substances move under that regime. The regulations also spell out who counts as a competent authority in Northern Ireland, including constables, HM Revenue and Customs officers, people authorised by the National Crime Agency and the Secretary of State. There is one small easing measure in the middle of all that paperwork: under the amended 2010 fee regulations, no fee is payable for import or export authorisations issued for movements of scheduled substances between Northern Ireland and Great Britain.

On the Great Britain side, the Government says it is correcting deficiencies left by the Windsor Framework and updating older retained EU wording so it works as secondary assimilated law in Great Britain. That includes refreshing outdated definitions, such as the meaning of 'natural product', and updating the annexes controlling certain drug precursor chemicals. The stated aim is alignment as much as tidy-up. The explanatory note says the annex changes bring the chemicals controlled in Great Britain into line with those already controlled in Northern Ireland under the EU regime. So while the legal routes diverge, the list of substances being watched is being pulled closer together.

The instrument also clears away provisions that no longer fit. Regulations 5 to 8 extend to England and Wales and Scotland only, while Regulation 9 and its Schedule extend to Northern Ireland only and revoke earlier instruments there so far as they apply in Northern Ireland. Some older forms in the 2015 delegated rules are also removed for Great Britain because, according to the explanatory note, they are no longer used. This is the sort of legislative housekeeping Whitehall often files as routine. But for firms, compliance teams and freight operators dealing with regulated goods across the Irish Sea, routine is not the same as irrelevant. A change in which legal text applies, which office signs off paperwork or whether a movement is treated as Great Britain, Northern Ireland or third-country trade can quickly become a real-world delay.

The Home Office says no full impact assessment has been produced because no, or no significant, effect on the private, voluntary or public sector is expected. That may be true in Westminster terms. Even so, the regulations are a reminder that the Windsor Framework is not an abstract constitutional argument. It reaches into technical fields like precursor chemicals and decides, line by line, where the UK still acts as one system and where it does not. For readers used to hearing that these issues sit far from daily life, this instrument tells a different story. The politics shows up in the paperwork. From 29 June 2026, anyone handling this corner of controlled drugs law will be working with a rulebook that still runs differently on either side of the Irish Sea.